Trials / Completed
CompletedNCT03514420
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Akcea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AKCEA-ANGPTL3-LRx | AKCEA-ANGPTL3-LRx solution for SC injection. |
Timeline
- Start date
- 2018-06-15
- Primary completion
- 2019-07-30
- Completion
- 2019-08-21
- First posted
- 2018-05-02
- Last updated
- 2021-02-16
- Results posted
- 2021-02-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03514420. Inclusion in this directory is not an endorsement.